激酶抑制剂-话题@MedSci

#激酶抑制剂#

80篇内容 | 2596人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2039873, encodeId=cad720398e3f6, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=CFDA批准上市口服多激酶抑制剂——Stivarga®（瑞戈非尼）审评概述，用于转移性结直肠癌患者, objectType=article, longId=121648, objectId=f3ab12164873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f3ab12164873, replyNumber=0, likeNumber=71, createdTime=2018-04-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f3ab12164873, moduleTitle=CFDA批准上市口服多激酶抑制剂——Stivarga®（瑞戈非尼）审评概述，用于转移性结直肠癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f3ab12164873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039866, encodeId=acb42039866cd, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, objectType=article, longId=100144, objectId=644a100144e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644a100144e7, replyNumber=0, likeNumber=100, createdTime=2017-11-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644a100144e7, moduleTitle=MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=644a100144e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039877, encodeId=c2dd20398e74a, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性, objectType=article, longId=130260, objectId=569b13026062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=569b13026062, replyNumber=0, likeNumber=60, createdTime=2018-06-04, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=569b13026062, moduleTitle=Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=569b13026062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039865, encodeId=8f022039865b3, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用, objectType=article, longId=99488, objectId=59bc994889c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59bc994889c, replyNumber=0, likeNumber=75, createdTime=2017-11-19, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59bc994889c, moduleTitle=Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59bc994889c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039874, encodeId=960020398e425, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Anesthesiology：Src激酶抑制剂减轻吗啡耐受而不影响增加效应或精神运动刺激, objectType=article, longId=122011, objectId=26fe12201126, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26fe12201126, replyNumber=0, likeNumber=59, createdTime=2018-01-01, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26fe12201126, moduleTitle=Anesthesiology：Src激酶抑制剂减轻吗啡耐受而不影响增加效应或精神运动刺激, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26fe12201126)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039870, encodeId=0b5720398e084, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, objectType=article, longId=111065, objectId=5e6c111065d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e6c111065d4, replyNumber=0, likeNumber=60, createdTime=2017-11-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e6c111065d4, moduleTitle=JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e6c111065d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039868, encodeId=3282203986838, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Graefes Arch Clin Exp Ophthalmol：药物治疗不佳的青光眼患者使用rho激酶抑制剂Ripasudil进行辅助性治疗一年后疗评估, objectType=article, longId=105920, objectId=50be10592068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=50be10592068, replyNumber=0, likeNumber=0, createdTime=2017-10-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=50be10592068, moduleTitle=Graefes Arch Clin Exp Ophthalmol：药物治疗不佳的青光眼患者使用rho激酶抑制剂Ripasudil进行辅助性治疗一年后疗评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=50be10592068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039861, encodeId=d5342039861db, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, objectType=article, longId=77494, objectId=d3b3e749422, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3b3e749422, replyNumber=0, likeNumber=83, createdTime=2017-03-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3b3e749422, moduleTitle=勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3b3e749422)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039864, encodeId=a3fa203986410, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Brit J Cancer：低密度脂蛋白胆固醇能够抵消酪氨酸激酶抑制剂对肾细胞上皮癌的抗肿瘤活性, objectType=article, longId=95153, objectId=4bce95153da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bce95153da, replyNumber=0, likeNumber=56, createdTime=2018-02-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bce95153da, moduleTitle=Brit J Cancer：低密度脂蛋白胆固醇能够抵消酪氨酸激酶抑制剂对肾细胞上皮癌的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4bce95153da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039863, encodeId=267b20398632b, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定, objectType=article, longId=88077, objectId=d1a0880e7c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1a0880e7c8, replyNumber=0, likeNumber=65, createdTime=2017-03-05, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1a0880e7c8, moduleTitle=Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1a0880e7c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039862, encodeId=2a602039862ca, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Blood：激酶抑制剂更佳序列治疗或为CLL患者带来持久的疗效, objectType=article, longId=80677, objectId=bcb1806e765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bcb1806e765, replyNumber=0, likeNumber=63, createdTime=2017-05-12, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bcb1806e765, moduleTitle=Blood：激酶抑制剂更佳序列治疗或为CLL患者带来持久的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bcb1806e765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039858, encodeId=924a2039858d5, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=CHEST：酪氨酸激酶抑制剂辅助治疗非小细胞肺癌疗效显著, objectType=article, longId=71967, objectId=255be196711, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=255be196711, replyNumber=0, likeNumber=75, createdTime=2017-04-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=255be196711, moduleTitle=CHEST：酪氨酸激酶抑制剂辅助治疗非小细胞肺癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=255be196711)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039860, encodeId=57ee20398605c, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, objectType=article, longId=74549, objectId=8dbde45490d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbde45490d, replyNumber=0, likeNumber=85, createdTime=2016-11-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbde45490d, moduleTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbde45490d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039859, encodeId=0a31203985943, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=AIM：酪氨酸激酶抑制剂疗效虽好，但增加的心血管事件也不容忽视哦, objectType=article, longId=74293, objectId=59dbe429332, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59dbe429332, replyNumber=0, likeNumber=72, createdTime=2016-12-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59dbe429332, moduleTitle=AIM：酪氨酸激酶抑制剂疗效虽好，但增加的心血管事件也不容忽视哦, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59dbe429332)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039857, encodeId=9b5f203985e6c, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析, objectType=article, longId=47552, objectId=24af4e552a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=24af4e552a1, replyNumber=0, likeNumber=68, createdTime=2016-01-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=24af4e552a1, moduleTitle=Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=24af4e552a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039856, encodeId=46142039856da, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗, objectType=article, longId=47374, objectId=d6104e37469, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6104e37469, replyNumber=0, likeNumber=71, createdTime=2015-09-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6104e37469, moduleTitle=JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6104e37469)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039854, encodeId=908820398546e, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=IJC：丁健等mTOR激酶抑制剂联合用药研究获进展, objectType=article, longId=34349, objectId=fa5834349bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa5834349bb, replyNumber=0, likeNumber=56, createdTime=2015-02-15, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa5834349bb, moduleTitle=IJC：丁健等mTOR激酶抑制剂联合用药研究获进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa5834349bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039855, encodeId=6f43203985525, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, objectType=article, longId=38055, objectId=fc3c38055d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc3c38055d3, replyNumber=0, likeNumber=71, createdTime=2015-01-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc3c38055d3, moduleTitle=FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc3c38055d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039853, encodeId=b029203985333, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=JID：新型钙离子依赖的蛋白激酶抑制剂可有效治疗隐孢子虫病, objectType=article, longId=24017, objectId=54f62401e46, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54f62401e46, replyNumber=0, likeNumber=66, createdTime=2013-10-11, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54f62401e46, moduleTitle=JID：新型钙离子依赖的蛋白激酶抑制剂可有效治疗隐孢子虫病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54f62401e46)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2039852, encodeId=c18f2039852ea, content=<a href='/topic/show?id=f7526685963' target=_blank style='color:#2F92EE;'>#激酶抑制剂#</a>, objectTitle=FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请, objectType=article, longId=6474, objectId=ccad64e4ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccad64e4ed, replyNumber=0, likeNumber=75, createdTime=2013-02-24, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccad64e4ed, moduleTitle=FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccad64e4ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

激酶抑制剂

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

CFDA批准上市口服多激酶抑制剂——Stivarga®（瑞戈非尼）审评概述，用于转移性结直肠癌患者

2018-04-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

MOL CANCER THER：非小细胞肺癌细胞对EGFR -酪氨酸激酶抑制剂埃罗替尼的敏感性

2017-11-03

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性

2018-06-04

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：治疗慢性淋巴细胞性白血病，新一代布鲁顿氏酪氨酸激酶抑制剂更少副作用

2017-11-19

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Anesthesiology：Src激酶抑制剂减轻吗啡耐受而不影响增加效应或精神运动刺激

2018-01-01

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JCO：激酶抑制剂可作为EGFR突变阳性晚期非小细胞肺癌的一线治疗！

2017-11-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Graefes Arch Clin Exp Ophthalmol：药物治疗不佳的青光眼患者使用rho激酶抑制剂Ripasudil进行辅助性治疗一年后疗评估

2017-10-18

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

勃林格血管激酶抑制剂Ofev（nintedanib）在欧美喜获治疗系统性硬化症（SSc）的孤儿药地位

2017-03-23

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Brit J Cancer：低密度脂蛋白胆固醇能够抵消酪氨酸激酶抑制剂对肾细胞上皮癌的抗肿瘤活性

2018-02-23

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：PIKfyve激酶抑制剂-阿匹莫德（apilimod）作为治疗B细胞非霍奇金淋巴瘤的鉴定

2017-03-05

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Blood：激酶抑制剂更佳序列治疗或为CLL患者带来持久的疗效

2017-05-12

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

CHEST：酪氨酸激酶抑制剂辅助治疗非小细胞肺癌疗效显著

2017-04-14

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加

2016-11-18

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

AIM：酪氨酸激酶抑制剂疗效虽好，但增加的心血管事件也不容忽视哦

2016-12-03

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

Lung Cancer：EGFR酪氨酸激酶抑制剂用于EGFR阳性突变的非小细胞肺癌的安全性分析

2016-01-14

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JNCI：PIM激酶抑制剂AZD1208 用于原癌基因导致的前列腺癌的治疗

2015-09-26

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

IJC：丁健等mTOR激酶抑制剂联合用药研究获进展

2015-02-15

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

FDA授予勃林格殷格翰激酶抑制剂nintedanib突破性疗法认定

2015-01-20

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

JID：新型钙离子依赖的蛋白激酶抑制剂可有效治疗隐孢子虫病

2013-10-11

smartjoy (审核中...)

前往app查看评论内容

#激酶抑制剂#

FDA批准BRAF激酶抑制剂药物CEP-32496的临床试验申请

2013-02-24

科室
- - 订阅+
  - 更多科室
工具
服务